Related Experiment Video
Updated: Jan 9, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Risk factors for pulmonary function alterations in children with metabolic dysfunction-associated fatty liver disease
Sen-Mao Xu1,2, Shu-Qin Wang3, Yao Xu4,5
1Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. dxsm82@163.com.
None:
Children with metabolic dysfunction-associated fatty liver disease (MAFLD) may exhibit abnormal lung function. However, it is unclear whether these abnormalities are independent of BMI. Moreover, the specific patterns of abnormal pulmonary function parameters have not been fully characterized, and the risk factors associated with impaired pulmonary function remain insufficiently understood. This study included 40 overweight or obese children with MAFLD and 30 overweight or obese control subjects without MAFLD. Pulmonary function parameters and anthropometric parameters were compared between children with MAFLD and the control group. Additionally, liver function, lipid and glucose metabolism, and cytokine levels were assessed. Multivariable regression analysis was used to identify risk factors for abnormal pulmonary function in children with MAFLD. No significant difference in BMI was observed between the groups (p = 0.075). Pulmonary function tests showed that FVC was significantly higher in children with MAFLD compared to controls (p < 0.001). In contrast, PEF, FEV1/FVC, FEF50, FEF75, and MMEF were lower in the MAFLD group (p < 0.05). Multivariable regression analysis demonstrated that HOMA-IR was significantly and inversely associated with FEF25 (b = -1.51, 95% CI: -2.33 to -0.69, p = 0.001), FEF50 (b = -1.85, 95% CI: -3.01 to -0.70, p = 0.003), and FEF75 (b = -1.44, 95% CI: -2.53 to -0.35, p = 0.01) among children with MAFLD. Furthermore, IL-1β levels were negatively correlated with MMEF (b = -1.16, 95% CI: -2.17 to -0.149, p = 0.03) and FEF50 (b = -0.63, 95% CI: -1.16 to -0.09, p = 0.02). These findings indicate that children aged 8 to 14 years with MAFLD exhibit higher FVC, along with a lower FEV1/FVC ratio and impaired small airway function compared to controls. This impairment in lung function is independent of BMI. Furthermore, HOMA-IR values and elevated IL-1β levels are key risk factors linked to abnormal small airway function.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion